All In Biotech

BLA 020521 · Ony

Infasurf Preservative Free

Calfactant · Intratracheal · Surfactant

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Aug 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jul 1, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

16

6 Phase 3, 2 recruiting

FAERS reports

63

60 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. INFASURF ® is a surfactant indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates < 29 weeks gestational age at risk for RDS. (1) for the rescue treatment of preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • INFASURF PRESERVATIVE FREE · CALFACTANT 35MG/ML · SUSPENSION, INTRATRACHEAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Calfactant" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • endotracheal intubation complication25
  • oxygen saturation decreased13
  • bradycardia6
  • cardio-respiratory arrest5
  • pneumothorax4
  • death3
  • heart rate decreased3
  • neonatal hypoxia3
  • obstruction3
  • product quality issue3
  • pulmonary haemorrhage3
  • bradycardia neonatal2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20071
20091
201316
20144
201510
201614
20174
20183
20193
20201
20211
20224

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 22 on PubMed

Sponsor: Ony

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.